Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators; Ghert M, Schneider P, Guyatt G, Thabane L, Vélez R, O'Shea T, Randall RL, Turcotte R, Wilson D, Wunder JS, Baptista AM, Cheng EY, Doung YC, Ferguson PC, Giglio V, Hayden J, Heels-Ansdell D, Khan SA, Sampath Kumar V, McKay P, Miller B, van de Sande M, Zumárraga JP, Bhandari M.
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
JAMA Oncol. 2022 Mar 1;8(3):345-353
DOI: doi: 10.1001/jamaoncol.2021.6628.
IF: 33.01
Gazendam AM, Schneider P, Vélez R, Ghert M; PARITY Investigators.
Tourniquet use in patients undergoing tumour resection and endoprosthetic reconstruction of the knee.
Bone Joint J. 2022 Oct;104-B(10):1168-1173
DOI: doi: 10.1302/0301-620X.104B10.BJJ-2022-0286.R1.
IF: 6.558
Vives J, Hernández J, Mirabel C, Puigdomenech-Poch M, Romeo-Guitart D, Marmolejo-Martínez-Artesero S, Cabrera-Pérez R, Jaramillo J, Kumru H, García-López J, Vidal-Samsó J, Navarro X, Coll-Bonet R.
Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance.
Cells. 2022 Jul 8;11(14):2153.
DOI: doi: 10.3390/cells11142153.
IF: 7.666
Lopez-Navas L, Torrents S, Sánchez-Pernaute R, Vives
Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies.
Stem Cells Transl Med. 2022 Aug 23;11(8):805-813
DOI: doi: 10.1093/stcltm/szac046.
IF: 7.655
Vives J, Sòria MG, McGrath E, Magri M.
The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance.
Cells. 2022 Jul 5;11(13):2112
DOI: doi: 10.3390/cells11132112.
IF: 7.666
